Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
One-Year Safety Study of Ruxolitinib Cream in Adolescents with Atopic Dermatitis
NCT05456529Phase 3Completed
- Sponsor
- Incyte
- Start
- Sep 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of ruxolitinib cream in atopic dermatitis (AD), sponsored by Incyte. Started Sep 2022; status: completed.
02
Drugs
ruxolitinib cream
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05456529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05456529.